YOTI
15.5.2020 13:38:10 CEST | Business Wire | Press release
GeneMe , a leading biotech company based in Gdańsk, Poland has developed “FRANKD” – a fast, scalable and reliable mouth swab test for COVID-19 that is completed on-premises in on average 13-25 minutes with no laboratory involvement. The GeneMe FRANKD test has been independently validated with 100% Sensitivity and 100% Specificity by Gdańsk University of Technology.
FRANKD requires less time to produce a result than the gold-standard RT-PCR (Reverse Transcriptase Polymerase Chain Reaction) reference test recommended by the World Health Organization. With consent, results are automatically issued on to each individual’s secure, free Yoti digital ID app . The test will cost businesses in the region of £10, making it cost-effective to perform mass daily testing and point-of-entry testing at care homes, airports, offices and many other locations.
Dawid Nidzworski Founder and CEO of GeneMe and developer of FRANKD said:
“We are extremely pleased with the quality of the FRANKD test and the contribution it will make towards the fight against the coronavirus pandemic and its damaging effects on public health and society
”.
FRANKD is currently in talks with governments and businesses across Europe to roll out millions of tests over the coming months, enabling key industries to test hundreds of thousands of employees daily, to help understand the spread of the virus and to monitor the infection R factor more accurately.
The test uses a patented enzyme rather than the currently scarce reagents used in RT-PCR tests to rapidly produce a definitive and reliable result. FRANKD is therefore scalable with 5m monthly tests expected from August. Use of a portable machine analyser to amplify the virus within the sample ensures high test accuracy. During June and July, FRANKD tests will be processed using hundreds of existing analyser machines, able to handle 90 tests every 30 minutes, but GeneMe expects affordable bespoke machines to be available from August.
What differentiates FRANKD from other viral testing solutions is that it is suitable for mass testing; 90 people can be tested at a time, every 30 minutes with one device, massively reducing the cost of testing. Testing on-premises by trained staff removes delays and the challenge of getting test samples to lab technicians to process. Independent validation of the FRANKD test is underway and European CE regulatory certification is expected by early June.
Testing care workers daily could dramatically reduce the spread of infection within the care home sector and beyond. Testing passengers prior to passing through airport security could also prevent disease spread during passenger air travel, reducing the need for mass quarantine. Testing all hotel guests and employees daily could allow hotels to reopen at significantly lower risk. A specific web application from Yoti will ensure all 90 tests within a batch are uniquely assigned to the correct owner before entering the analyser machine.
Individuals use the secure, free Yoti digital ID app to link themselves to their test and, with consent, the digital test result is automatically added into the tested person’s Yoti. Organisations including the NHS already securely issue digital ID cards using the Yoti app credential management platform. Individuals can present or share their tamperproof, verified details with other parties in seconds - including their test result - whether in person or online, with a tap of a button or scan of a QR code.
Anti-fraud measures are built into Yoti’s reusable digital ID, critically offering much higher trust than is possible with traditional paper and plastic-based identity documents or paper health certificates. Audit receipts are issued securely to both the individual and the recipient individual or organisation when results are shared remotely. The Yoti app is currently available in English, with French, Spanish, Polish and German to be released shortly, followed by further languages.
Kasjan Szemiako
- CTO of GeneMe and developer of FRANKD said:
“We chose Yoti because of its security, user interface and reputation. We will share the results of the test directly with Yoti to ensure data privacy and enable user control
.”
Robin Tombs
- Yoti Co-Founder and CEO said:
“We’re delighted FRANKD has chosen Yoti to enable individuals to manage their COVID-19 test results securely on their phone. Getting the world of business and sport back up and running safely during this coronavirus pandemic is so important. Get FRANKD with Yoti.”
===ENDS===
About FRANKD
Contact colin@nexd.partners or visit www.geneme.eu
GeneMe develops, registers and produces diagnostic kits for the detection of SARS-CoV-2 and over 240 other pathogens. All kits are based on direct virus RNA detection in a sample.
GeneMe uses a special patented enzyme for virus detection.
Test results were validated by the Gdańsk University of Technology.
Test Sensitivity results show that the average detection time for a sample containing 1 million viral copies was 12 minutes 45 seconds, and for 10 viral copies was 23 minutes 25 seconds. A German study has reported that an COVID-19 infected individual has an average of 670,000 viral copies per swab during the first 5 days of their illness. https://www.medrxiv.org/content/medrxiv/early/2020/03/08/2020.03.05.20030502.full.pdf
The GeneMe FRANKD test requires less time to produce a result than the gold-standard RT-PCR reference test recommended by the World Health Organization.
Test Specificity results show that no false positives were obtained when testing against 4 other coronaviruses.
FRANKD - stands for Fast, Reliable, Accurate, No laboratory and available in a Kit form to be used on-premises Daily.
Dawid Nidzworski one of the Co-founder’s of GeneMe is also the creator of the Institute of Biotechnology and Molecular Medicine (IBMM).
The Institute of Biotechnology and Molecular Medicine (IBMM) is an independent, elite, biomedical research institution. The thematic scope of IBMM activities includes, among others, biotechnology, medicine, diagnostics, molecular biology and material engineering.
More on www.ibmm.pl
About Yoti
Contact Covid19@yoti.com or visit www.yoti.com .
Yoti is a digital ID and credential management platform that allows organisations to verify identities and trusted credentials online and in person. Yoti’s products span identity verification, age assurance, document e-signing, access management and biometric authentication.
Yoti is certified to ISO/IEC 27001:2013 for ID Verification Services. Yoti is ISAE 3000 (SOC 2), Type 2 certified for its technical and organisational security processes and is a Secured by Design (Official Police Security Initiative) member company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200515005230/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TwentyTwo Real Estate to Acquire Terhills Resort in Belgium from LRM18.5.2026 15:00:00 CEST | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces it has agreed to acquire Terhills Resort in Belgium from LRM. The transaction is expected to close on 29 May 2026. Operated by Center Parcs, the premium holiday park spans 63 hectares and comprises 250 waterfront cottages alongside central leisure facilities, set within a unique natural environment at the gateway to Hoge Kempen National Park. Center Parcs will remain the operator of the resort for at least the next 10 years, ensuring continuity for guests and supporting the long-term positioning of the resort as a leading leisure destination in Limburg, one of Flanders’ most distinctive tourism regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513424487/en/ Opened in 2021, Terhills Resort forms part of the broader long-term transformation of the surrounding area into a leading nature, tourism and leisure destination.
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden18.5.2026 14:30:00 CEST | Press release
The state-of-the-art facility enhances support for complex modalities across all phases of drug developmentKey facts Thermo Fisher opensnew bioanalytical and biomarker laboratory in Gothenburg, Sweden Designed to deliver comprehensive, full-service bioanalytical and biomarker solutions Supports pharmaceutical and biotechnology customers across all phases of drug development Helps customers globally accelerate innovation and bring new therapies to patients faster Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company’s global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development. With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the laboratory provides rapid, reliable bioanalytical and biomarker servi
HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion18.5.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has received approval from the Taiwan Food and Drug Administration (TFDA) for the Edison® System, representing a significant milestone in the company’s global expansion efforts and continued growth across Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518694013/en/ HistoSonics Edison® Histotripsy System Taiwan is widely recognized as one of the most advanced and strategically important medical device markets in the region, known for its rigorous regulatory standards and highly innovative physician community. The TFDA approval process included a detailed review of the company’s clinical and regulatory submission package and concluded with unanimous agreement from committee members. The approval further reinforces the growing clinical and regulatory momentum behind histotripsy, a non-invasive, non-th
FurtherAI Appoints Tom Bradley to Lead UK and EU Expansion18.5.2026 14:00:00 CEST | Press release
FurtherAI, the AI platform purpose-built for insurance, today announced the appointment of Tom Bradley to lead its UK and EU operations. This marks a significant step in FurtherAI's international expansion, as the company moves to establish a local presence in one of the world's most important insurance markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518611218/en/ FurtherAI Appoints Tom Bradley to lead UK & EU expansion FurtherAI is already working with leading partners in the UK, and Tom's appointment will allow the company to deepen those relationships, build a local team, and serve the rapidly growing demand from carriers, MGAs, and brokers across the Lloyd's market and the wider region. A market moving fast on AI The Lloyd's market and the broader UK and European insurance ecosystem are adopting AI at a pace few would have predicted even twelve months ago. From submission gateways to policy audits to claims, o
Bending Spoons Closes Acquisition of Tractive18.5.2026 13:48:00 CEST | Press release
Technology company Bending Spoons today announced that it has closed the acquisition of Tractive, an Austria-based global leader in location tracking and health monitoring for pets. The definitive acquisition agreement was entered into in March 2026. Michael Hurnaus, Tractive’s CEO and co-founder, said of the acquisition: “Building Tractive into a global leader in pet safety over the past thirteen years has been an extraordinary journey. We set out to give pet owners peace of mind, and grew that mission into a product trusted by millions of people across the world. I'm proud of everything the team has achieved, and excited about how far Tractive will reach under Bending Spoons. Their global platform and technological capabilities will help keep Tractive at the cutting edge, combining our strong European innovation culture with the scale needed to reach even more pet parents around the world.” Luca Ferrari, the Bending Spoons CEO and co-founder, today said: “We’re impressed by what the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
